Ziopharm Oncology announces publication of positive results of phase 1 monotherapy trial
Ziopharm Oncology announced publication of its phase 1 trial of Controlled IL-12 in patients with recurrent glioma in the journal Science Translational Medicine. The publication: “Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial.” August 14, 2019